LOGIN  |  REGISTER
Assertio

Molina Healthcare Announces Second Quarter 2025 Earnings Release and Conference Call Dates

June 04, 2025 | Last Trade: US$240.97 1.97 0.82

LONG BEACH, Calif. / Jun 04, 2025 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the second quarter ending June 30, 2025, after the market closes on Wednesday, July 23, 2025, and will host a conference call and webcast to discuss the earnings release on Thursday, July 24, 2025, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 4784585. A telephonic replay of the conference call will be available through Thursday, July 31, 2025, by dialing (877) 344-7529 and entering the confirmation number, 9484867.

A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

Viking Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page